| __timestamp | Sarepta Therapeutics, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 49315000 | 72471000 |
| Thursday, January 1, 2015 | 75043000 | 89204000 |
| Friday, January 1, 2016 | 83749000 | 106010000 |
| Sunday, January 1, 2017 | 122682000 | 137905000 |
| Monday, January 1, 2018 | 207761000 | 159888000 |
| Tuesday, January 1, 2019 | 284812000 | 158425000 |
| Wednesday, January 1, 2020 | 317875000 | 200677000 |
| Friday, January 1, 2021 | 282660000 | 304759000 |
| Saturday, January 1, 2022 | 451421000 | 377221000 |
| Sunday, January 1, 2023 | 481871000 | 336361000 |
Unleashing insights
In the competitive landscape of biopharmaceuticals, understanding the financial strategies of industry leaders is crucial. Over the past decade, from 2014 to 2023, Sarepta Therapeutics, Inc. and Supernus Pharmaceuticals, Inc. have demonstrated distinct trends in their Selling, General, and Administrative (SG&A) expenses.
Sarepta Therapeutics has seen a staggering increase of over 870% in SG&A expenses, peaking in 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Supernus Pharmaceuticals experienced a more moderate rise of approximately 360%, with a notable surge in 2021, indicating strategic scaling efforts.
These trends highlight the differing approaches to growth and market positioning. While Sarepta's rapid increase suggests a focus on scaling operations, Supernus's steady rise points to a more measured expansion strategy. Understanding these financial trajectories offers valuable insights into the operational priorities of these biopharma leaders.
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? AbbVie Inc. or Supernus Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Zoetis Inc. or Sarepta Therapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Sarepta Therapeutics, Inc. or Evotec SE
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Supernus Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Supernus Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.